Muna Qayed
YOU?
Author Swipe
View article: Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients
Impact of Age on Graft-vs-Host Disease and Overall Survival in Pediatric Hematopoietic Cell Transplant Recipients Open
Advances in graft-versus-host disease (GVHD) prevention and treatment have resulted in expanded donor options and improvement in treatment-related mortality (TRM). This analysis aimed to compare the incidence of acute and chronic GVHD (aGV…
View article: Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation
Upper and Lower Respiratory Tract Compartmentalization in Pediatric Stem Cell Transplantation Open
Rationale Lung injury after hematopoietic stem cell transplantation (HCT) occurs due to infection, chemotherapy toxicity, and alloreactive inflammation. Analyses of bronchoalveolar lavage (BAL) fluid have revealed dominant pathobiologic si…
View article: Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation
Distinct Biological Subtypes of Chronic GVHD after Pediatric Hematopoietic Cell Transplantation Open
Chronic graft-versus-host-disease (cGvHD) is the primary non-relapse limitation to a successful hematopoietic cell transplantation (HCT) and is largely treated as a single biological entity. We hypothesized that there exist different biolo…
View article: Endotheliopathy syndromes, TA-TMA, and SOS, are risk factors for morbidity and mortality in critically ill pediatric hematopoietic cell transplant recipients
Endotheliopathy syndromes, TA-TMA, and SOS, are risk factors for morbidity and mortality in critically ill pediatric hematopoietic cell transplant recipients Open
Background Pediatric hematopoietic cell transplant (HCT) recipients who require intensive care unit (PICU) admission historically have high mortality rates. The HCT landscape is rapidly changing with the incorporation of novel graft versus…
View article: Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort
Identification of Distinct Subtypes in Immune Tolerance after Hematopoietic Cell Transplantation Using the Prospective ABLE1.0 Pediatric Study Cohort Open
The lack of immune tolerance after hematopoietic cell transplantation (HCT) can result in chronic graft-versus-host disease (cGvHD), which is the primary nonrelapse limitation of successful HCT. To date, immune tolerance has been considere…
View article: The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD Open
Changes in the clinical symptoms of acute graft-versus-host disease (GVHD) are currently used to assess treatment responses. The Mount Sinai Acute GVHD International Consortium (MAGIC) consortium has recently revealed that the integration …
View article: Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant
Integrating pulmonary and systemic transcriptomes to characterize lung injury after pediatric hematopoietic stem cell transplant Open
Hematopoietic stem cell transplantation (HCT) is a potentially life-saving therapy but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulationWe previously showed that bronchoalveolar lavage (BAL) transc…
View article: Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel
Characterization and prediction of prolonged severe neutropenia in pediatric patients receiving tisagenlecleucel Open
Hematotoxicity is the most frequent severe toxicity after chimeric antigen receptor T-cell (CAR-T) therapy. However, limited data exist on risk factors and outcomes for hematotoxicity for children and young adults (CAYAs) with B-acute lymp…
View article: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Open
PURPOSE Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for advanced hematologic malignancies. HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with inferior survival. …
View article: Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant
Integrating Pulmonary and Systemic Transcriptomic Profiles to Characterize Lung Injury after Pediatric Hematopoietic Stem Cell Transplant Open
Hematopoietic stem cell transplantation (HCT) is potentially curative for numerous malignant and non-malignant diseases but can lead to lung injury due to chemoradiation toxicity, infection, and immune dysregulation. Bronchoalveolar lavage…
View article: Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy Open
Tisagenlecleucel (tisa-cel) and brexucabtagene autoleucel (brexu-cel) are approved CD19 chimeric antigen receptor T-cell therapy (CAR T) products for young adults (YA) with relapsed/refractory B-cell acute lymphoblastic leukemia. A distinc…
View article: The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes
The Impact of Structural Inequity and Adverse Social Determinants of Health on Hematopoietic Cell Transplant Access in Pediatric Patients with Hematologic Malignancies and Myelodysplastic Syndromes Open
Introduction: Without prompt hematopoietic cell transplantation (HCT) in eligible patients, disease-free and overall survival rates remain low. Despite this, many studies conducted primarily in adults have shown significant disparities in …
View article: Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd
Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd Open
Background: The majority of patients respond to steroid treatment for graft-vs-host disease (GVHD), but the typically high doses and prolonged courses can cause substantial morbidity. GVHD can be classified at onset into two groups with si…
View article: Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant
Pentostatin Low-Dose TBI Is an Effective Conditioning Regimen That Permits Donor Engraftment in Patients with High Co-Morbidities Undergoing the First Transplant or Prior to a Second Transplant Open
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for malignant and nonmalignant hematological disease patients. Despite initial engraftment in the great majority of patients, the abilit…
View article: A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT)
A Pilot Multi-Pronged Approach to Measuring Endothelial Dysfunction and Predict the Development of Endothelial Disorders and Death Post Hematopoietic Cell Transplantation (HCT) Open
Background: Endothelial dysfunction is a key driver of transplant associated thrombotic microangiopathy (TA-TMA) and sinusoidal obstructive syndrome (SOS)- early syndromes post hematopoietic cell transplantation, which are associated with …
View article: Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis
Ibrutinib for therapy of steroid-refractory chronic graft-versus-host disease: a multicenter real-world analysis Open
To examine the activity of ibrutinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) after the US Food and Drug Administration approval, we conducted a multicenter retrospective study. Data were standardly collected (N =…
View article: Evaluation of the Axillary Reverse Mapping Technique in Preventing Breast Cancer-Related Post Operative Lymphedema, Ain Shams University Initial Experience
Evaluation of the Axillary Reverse Mapping Technique in Preventing Breast Cancer-Related Post Operative Lymphedema, Ain Shams University Initial Experience Open
Background Management of breast cancer patients with clinically positive nodes is a field of research and axillary lymph nodes dissection is still an acceptable option for them. However it affects the patient quality of life in the form of…
View article: Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation
Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation Open
Abatacept plus calcineurin inhibitors/methotrexate (CNI/MTX) is the first US Food and Drug Administration (FDA)-approved regimen for acute graft-versus-host disease (aGVHD) prophylaxis during unrelated-donor hematopoietic cell transplantat…
View article: Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD Open
Acute graft-versus-host disease (GVHD) grading systems that use only clinical symptoms at treatment initiation such as the Minnesota risk identify standard and high-risk categories but lack a low-risk category suitable to minimize immunosu…
View article: The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD Open
The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GV…
View article: Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD Open
Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination…
View article: Age, <scp>GVHD</scp> prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary <scp>CIBMTR</scp> analysis
Age, <span>GVHD</span> prophylaxis, and timing matter in thrombotic microangiopathy after haematopoietic cell transplantation—A secondary <span>CIBMTR</span> analysis Open
Summary Most reports of risk factors (RF) for developing transplant‐associated thrombotic microangiopathy (TA‐TMA) and death are derived from paediatric and young adult cohorts, with minimal data on differences in RF and outcomes by age. I…
View article: Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation
Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation Open
Hematopoietic cell transplantation (HCT) uses cytotoxic chemotherapy and/or radiation followed by intravenous infusion of stem cells to cure malignancies, bone marrow failure and inborn errors of immunity, hemoglobin and metabolism. Lung i…
View article: Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication Open
Virus-specific T cells (VST) from partially-HLA matched donors have been effective for treatment of refractory viral infections in immunocompromised patients in prior studies with a good safety profile, but rare adverse events have been de…
View article: Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis Open
The absence of a standardized definition for graft-versus-host disease (GVHD) flares and data on its clinical course are significant concerns. We retrospectively evaluated 968 patients across 23 Mount Sinai Acute GVHD International Consort…
View article: A Day 14 Endpoint for Acute GVHD Clinical Trials
A Day 14 Endpoint for Acute GVHD Clinical Trials Open
The overall response rate (ORR) 28 days after treatment has been adopted as the primary endpoint for clinical trials of acute graft versus host disease (GVHD). However, physicians often need to modify immunosuppression earlier than day (D)…
View article: <scp>D</scp>‐dimer and sinusoidal obstructive syndrome‐novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study
<span>D</span>‐dimer and sinusoidal obstructive syndrome‐novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study Open
Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a common, severe complication of allogeneic hematopoietic cellular therapy (HCT). Even when treated in many studies, morbidity and mortality rates are high. This prospective sing…